The question of the use of Andexxa, a reversal agent for Factor Xa Inhibitors, has been batting around my brain for a few months now. We are in the unfortunate position of having a drug with very questionable evidentiary support but with an FDA labelled indication. I received an email from the lead author of paper just published in Neurocritical Care.
- Peled et al. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 10.1007/s12028-019-00866-6
Dr. Harry Peled is the medical director of Cardiology and Critical Care at St Jude Medical Center in California. Relevantly, he is also chair of the Pharmacy an Therapeutics Committee.
I would love to hear your thoughts on this issue–place them in the comments below.
See Also
Update:
Additional New Information
More on EMCrit
- EMCrit 319 – Safe and Smart Reversal of Anticoagulation / Anti-platelet Agents in 2022
- Podcast 203 – New Reversals for New Anticoagulants with Nadia Awad
Additional Resources
You Need an EMCrit Membership to see this content. Login here if you already have one.
- EMCrit 378 – So NSTI – Necrotizing Fasciitis & Life Threatening Soft Tissue Infections - June 29, 2024
- EMCrit Wee – Adaptive Support Ventilation (ASV) - June 24, 2024
- EMCrit RACC-Lit Review for June 2024 - June 18, 2024